Structure Therapeutics' stock has declined over 40% since last year, but its differentiated technology platform and promising drug pipeline still support a "Buy" rating. Structure's lead candidate, ...
Structure Therapeutics saw its newly-public U.S. American Depositary Shares (ADSs) rise 70% on their first day of trading, after completing a $161 million initial public offering (IPO)—by far the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback